AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Validation of the D-TAP Parental Questionnaire for Early Screening of Pediatric Feeding Disorder in Hospitalized Children Aged 8 to 18 Months

Recruitingn/aAges 8 Months - 18 MonthsAllUniversity Hospital, Strasbourg, France
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This single-center observational study aims to evaluate the validity of the D-TAP parental questionnaire for early screening of pediatric feeding disorder (PFD) in hospitalized children aged 8 to 18 months. Currently, no standardized screening test is routinely used by all healthcare professionals in France to identify PFD, despite its reported prevalence and potential consequences for child development, family well-being, and healthcare costs. The D-TAP questionnaire will be compared with the Montreal Children's Hospital Feeding Scale. A blinded clinical speech-language pathology assessment of information collected during a semi-structured parental interview will be used to identify signs suggestive of PFD. A total of 100 children will be included. The study will assess the diagnostic performance of the D-TAP questionnaire, identify an optimal screening threshold, and explore whether

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Children aged 8 to 18 months, inclusive, receiving care within the pediatric medical-surgical department at the Hautepierre site. * Children born at or after 37 weeks of gestation. Parents who are French-speaking. * Parents affiliated with a social security or health insurance scheme. * Parents who have agreed to participate in the study. Exclusion Criteria: * Parents who refuse participation. * Children diagnosed with a neurodevelopmental disorder. * Children with oromyofacial malformations. * Children with digestive conditions affecting oral feeding, including esophageal achalasia, esophageal atresia, necrotizing enterocolitis, gastroschisis, Hirschsprung disease, eosinophilic esophagitis, omphalocele, chronic intestinal pseudo-obstruction, or short bowel syndrome. * Children with neurological conditions affecting feeding, including pediatric stroke, spinal muscular atrophy, developmental and epileptic encephalopathies, congenital myopathies, cerebral palsy, CHARGE syndrome, congenital myasthenic syndromes, Prader-Willi syndrome, Rett syndrome, Smith-Lemli-Opitz syndrome, traumatic brain injury, or trisomy. * Children with a history of prolonged hospitalization or invasive care during the neonatal period. * Children currently receiving or previously having received artificial nutrition, whether enteral or parenteral.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
Pediatric Surgery Department, Hautepierre Hospital, University Hospital of Strasbourg, France
Strasbourg, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy